Tag Archive for: AMR

Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals

/in

Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]

Read more

Novo Holdings participates in EUR 30 million Series A financing of Bactolife, a Danish biotech company dedicated to strengthening the gut microbiome and fighting antimicrobial resistance

/in

Novo Holdings today announced it has participated in the EUR 30 million Series A Financing of Bactolife. ATHOS led the round, with participation from the Bill & Melinda Gates Foundation, Novo Holdings and other existing investors. Bactolife is a Danish bioindustrial company developing proprietary Binding Proteins™, which strengthen the gut microbiome of humans and animals […]

Read more

Destiny Pharma plc – Positive findings from recent SAB meeting

/in

Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for XF-73 Nasal Brighton, United Kingdom – 6 July 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, recently held a meeting with its Scientific Advisory Board […]

Read more

Destiny Pharma plc – Dr Debra Barker Appointed Interim CEO

/in

Brighton, United Kingdom – 25th May 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces, ahead of the AGM, that Neil Clark has decided to step down as Chief Executive Officer to pursue new challenges. Neil will also step down […]

Read more

Destiny Pharma plc – Fundraising to raise up to £8 million

/in

Fundraising to raise up to £8 million Destiny Pharma plc (AIM: DEST) (the “Company” or “Destiny Pharma”), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces a conditional fundraising of up to approximately £8 million (before expenses) comprising a Placing, Subscription and an Open Offer (each as defined below). The […]

Read more